"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
| Descriptor ID |
D018796
|
| MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 5 | 0 | 5 |
| 1997 | 6 | 0 | 6 |
| 1998 | 6 | 0 | 6 |
| 1999 | 7 | 0 | 7 |
| 2000 | 7 | 0 | 7 |
| 2001 | 10 | 0 | 10 |
| 2002 | 6 | 0 | 6 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 5 | 1 | 6 |
| 2021 | 2 | 0 | 2 |
| 2022 | 5 | 0 | 5 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928.
-
Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study. J Clin Oncol. 2024 Oct; 42(28):3330-3338.
-
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat. 2024 Nov; 208(1):203-214.
-
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024 Aug 20; 42(24):2860-2872.
-
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 07; 389(23):2162-2174.
-
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824.
-
The evolving therapeutic landscape of antibody-drug conjugates in breast cancer. Expert Rev Anticancer Ther. 2022 12; 22(12):1325-1331.
-
In Reply. Oncologist. 2022 10 01; 27(10):e827-e828.
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
-
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 04; 23(4):540-552.